摘要
目的评价国产托卡朋片剂治疗帕金森病(PD)的有效性。方法观察PD患者80例,采用随机、双盲、安慰剂对照、平行分组研究。将PD患者随机分为托卡朋片治疗组和安慰剂组,治疗组41例,安慰剂组39例,给予观察药物托卡朋片或安慰剂1片,每天3次,总观察时间为26周。疗效指标采用国际通用的评价PD症状的UPDRS评分。结果PD患者治疗26周后,用UPDRS评分从认知功能、震颤、肌僵直、运动减少和自主神经等方面进行比较。托卡朋组PD患者在认知功能、肌僵直、随意运动减少等项目较安慰剂组有明显改善(P均<0.05)。口服托卡朋后自主神经症状和震颤的UPDRS评分同安慰剂组比较差异无显著性(P均>0.05)。结论儿茶酚-O位-甲基转移酶(COMT)抑制剂托卡朋能够改善PD的运动功能,尤其是运动减少和肌僵直,同时能改善患者的认知功能。
Objective To assess the eficacy of tolcapone in the treatment of Parkinson＇s disease （PD）. Methods 80 patients with PD were followed up in a multicentre, double-blind, placebo-controlled, randomized trial for 26 weeks. UPDRS score was used to evaluate the efficacy of tolcapone in the treatment of PD. 80 patients were randomly divided into tolcapone group and placebo group. 80 PD patients were given tolcapone 100 mg or placebo, t. i. d, for 26 weeks. Results （ 1 ） There was no significant difference in patients＇ characters, history, initial symptoms and UPDRS between two groups. （2） The patients＇cognition ability, muscle rigidity, tremor, hypokinesia and the function of autonomic nerve were improved significantly in tolcapone group, as compared with those in placebo group by UPDRS score （ P 〈 0.05, P 〈 0.05, P 〈 0.05, respectively）. But there were no significant differences in the aspects of tremor and the function of autonomic nerve between tolcapone group and placebo group （ P 〈 0.05, P 〈 0.05, respeetively）. Conclusion Tolcapone could greatly improve PD patients＇ motor function, especially in hypokinesia, muscle rigidity, and which could also improve patient＇s cognition ability.
出处
《河北医药》
CAS
2006年第3期171-173,共3页
Hebei Medical Journal
